WO2009127922A3 - Préparation pharmaceutique pour traiter une maladie cardio-vasculaire - Google Patents

Préparation pharmaceutique pour traiter une maladie cardio-vasculaire Download PDF

Info

Publication number
WO2009127922A3
WO2009127922A3 PCT/IB2009/000331 IB2009000331W WO2009127922A3 WO 2009127922 A3 WO2009127922 A3 WO 2009127922A3 IB 2009000331 W IB2009000331 W IB 2009000331W WO 2009127922 A3 WO2009127922 A3 WO 2009127922A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
drugs
immediate
extended
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/000331
Other languages
English (en)
Korean (ko)
Other versions
WO2009127922A2 (fr
Inventor
김성욱
전성수
구자성
김진욱
박선우
장석영
이상주
조영관
이준영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanall Pharmaceutical Co Ltd
Original Assignee
Hanall Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Pharmaceutical Co Ltd filed Critical Hanall Pharmaceutical Co Ltd
Publication of WO2009127922A2 publication Critical patent/WO2009127922A2/fr
Publication of WO2009127922A3 publication Critical patent/WO2009127922A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une préparation pharmaceutique contenant un compartiment à libération immédiate et un compartiment à libération prolongée. Le compartiment à libération immédiate comprend un médicament statine à effet hypolipémiant, son isomère ou un sel pharmaceutiquement acceptable utilisé comme principe pharmacologiquement actif et le compartiment à libération prolongée contient une dihydropyridine inhibitrice des canaux calciques, son isomère ou son sel pharmaceutiquement acceptable utilisée comme principe pharmacologiquement actif. La préparation combinée de médicament statine à effet hypolipémiant à libération immédiate et de dihydropyridine inhibitrice des canaux calciques à libération prolongée, est pharmacologiquement, cliniquement, scientifiquement et économiquement plus utile que la préparation simple de chacun de ces médicaments ou qu'une combinaison simple de ces médicaments, dans la prévention et le traitement de maladie cardio-vasculaire, de maladies cardio-pulmonaire, de maladie pulmonaire, ou de maladie rénale, chez des patients atteints de syndrome métabolique et résistants à l'insuline et chez des patients souffrant de diabète ou dont on soupçonne un prédiabète. La préparation de la présente invention permet différentes durées de libération pour le médicament statine à effet hypolipémiant et pour la dihydropyridine inhibitrice des canaux calciques, et empêche ainsi l'antagonisme mutuel et les effets indésirables entre les deux médicaments et permet une administration facile aux patients prenants simultanément les deux médicaments.
PCT/IB2009/000331 2008-02-22 2009-02-23 Préparation pharmaceutique pour traiter une maladie cardio-vasculaire Ceased WO2009127922A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0016516 2008-02-22
KR20080016516 2008-02-22

Publications (2)

Publication Number Publication Date
WO2009127922A2 WO2009127922A2 (fr) 2009-10-22
WO2009127922A3 true WO2009127922A3 (fr) 2009-12-10

Family

ID=41199515

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2009/000331 Ceased WO2009127922A2 (fr) 2008-02-22 2009-02-23 Préparation pharmaceutique pour traiter une maladie cardio-vasculaire
PCT/IB2009/006277 Ceased WO2009127974A2 (fr) 2008-02-22 2009-02-23 Préparation pharmaceutique pour le traitement de maladies cardiovasculaires

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/006277 Ceased WO2009127974A2 (fr) 2008-02-22 2009-02-23 Préparation pharmaceutique pour le traitement de maladies cardiovasculaires

Country Status (2)

Country Link
KR (5) KR20090091084A (fr)
WO (2) WO2009127922A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101143559B1 (ko) 2009-09-25 2012-05-24 기아자동차주식회사 오일유로 통합형 엔진브레이크 장치
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
JP2015503555A (ja) * 2012-05-11 2015-02-02 ハナル・バイオファーマ・カンパニー・リミテッド ボセンタン制御放出性経口製剤
KR20140001357A (ko) * 2012-06-26 2014-01-07 현대약품 주식회사 아세브로필린을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
CN104161960A (zh) * 2014-09-02 2014-11-26 济南超舜中药科技有限公司 一种治疗肺心病的醋饮及其制备方法
WO2016138072A1 (fr) 2015-02-27 2016-09-01 Ecolab Usa Inc. Compositions pour récupération améliorée de pétrole
PL3320903T3 (pl) * 2015-07-08 2021-12-06 Hk Inno.N Corporation Kompozycja farmaceutyczna zawierająca amlodypinę, walsartan i rosuwastatynę
US10413543B2 (en) 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
US10808165B2 (en) 2016-05-13 2020-10-20 Championx Usa Inc. Corrosion inhibitor compositions and methods of using same
CA3029400A1 (fr) 2016-06-28 2018-01-04 Ecolab Usa Inc. Composition, procede et utilisation pour la recuperation assistee du petrole
KR20190043076A (ko) * 2017-10-17 2019-04-25 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
KR102265977B1 (ko) * 2018-07-16 2021-06-16 주식회사 코피텍 방습성이 개선된 필름 코팅용 조성물 및 이를 코팅한 정제
CA3203975A1 (fr) 2020-12-03 2022-06-09 Battelle Memorial Institute Compositions de nanoparticules polymeres et de nanostructures d'adn et procedes d'administration non virale
CA3216359A1 (fr) 2021-04-07 2022-10-13 Battelle Memorial Institute Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux
KR102730602B1 (ko) * 2021-06-24 2024-11-18 주식회사 종근당 칸데사르탄, 암로디핀 및 아토르바스타틴을 포함하는 약제학적 복합제제
KR102608853B1 (ko) * 2021-11-15 2023-12-01 재단법인 아산사회복지재단 대사질환 개선용 생체발광 캡슐
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (fr) 2023-12-08 2025-06-12 Battelle Memorial Institute Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022385A (ko) * 1997-08-29 2001-03-15 실버스타인 아써 에이. 암로디핀 및 스타틴 화합물을 포함하는 복합 조성물
KR20040025889A (ko) * 2001-01-26 2004-03-26 쉐링 코포레이션 혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와심혈관성 제제의 조합물
KR20070078625A (ko) * 2006-01-27 2007-08-01 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
KR20080018841A (ko) * 2006-08-24 2008-02-28 한올제약주식회사 방출성이 제어된 디히드로피리딘계 칼슘길항제/스타틴계지질저하제의 복합제제

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050016452A (ko) * 2002-05-29 2005-02-21 노파르티스 아게 Ｄｐｐ ⅳ 억제제와 심혈관계 화합물의 조합물
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022385A (ko) * 1997-08-29 2001-03-15 실버스타인 아써 에이. 암로디핀 및 스타틴 화합물을 포함하는 복합 조성물
KR20040025889A (ko) * 2001-01-26 2004-03-26 쉐링 코포레이션 혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와심혈관성 제제의 조합물
KR20070078625A (ko) * 2006-01-27 2007-08-01 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
KR20080018841A (ko) * 2006-08-24 2008-02-28 한올제약주식회사 방출성이 제어된 디히드로피리딘계 칼슘길항제/스타틴계지질저하제의 복합제제

Also Published As

Publication number Publication date
KR20090091083A (ko) 2009-08-26
WO2009127974A2 (fr) 2009-10-22
KR20090091080A (ko) 2009-08-26
KR20090091077A (ko) 2009-08-26
WO2009127922A2 (fr) 2009-10-22
KR101181172B1 (ko) 2012-09-18
KR20090091085A (ko) 2009-08-26
KR20090091084A (ko) 2009-08-26
WO2009127974A3 (fr) 2010-03-25
KR101207618B1 (ko) 2012-12-04

Similar Documents

Publication Publication Date Title
WO2009127922A3 (fr) Préparation pharmaceutique pour traiter une maladie cardio-vasculaire
WO2008027557A3 (fr) Compositions à base de topiramate et méthodes permettant d'en augmenter la biodisponibilité
WO2009134057A3 (fr) Formulation pharmaceutique contenant un agent bloquant les récepteurs de l'angiotensine ii
US20090253728A1 (en) Methods and Compositions for Treating Nociceptive Pain
WO2009125981A3 (fr) Formulation pharmaceutique
WO2007103557A3 (fr) Revêtement de capsules avec des ingrédients pharmaceutiques actifs
Lee et al. Fimasartan: a new angiotensin receptor blocker
EP2371853A3 (fr) Dérivés d'insuline ou ses sels pharmaceutiquement acceptables, composition pharmaceutique, utilisation du dérivé d'insuline et son sel pharmaceutiquement acceptable et procédé de traitement
WO2009104932A3 (fr) Préparation composite
JP2019517542A5 (fr)
WO2009134076A3 (fr) Composition combinée pour la libération contrôlée d'un agent bloquant le récepteur angiotensine ii et d'un inhibiteur de la réductase hmg-coa
WO2009022821A3 (fr) Préparation combinée contenant un inhibiteur de hmg-coa reductase et aspirine et son procédé d'élaboration
WO2008136392A1 (fr) Préparation pour une administration orale
JP6174666B2 (ja) ナルトレキソンの徐放型配合物
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
WO2007146900A3 (fr) Procédé de traitement antihypertenseur
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
MX2015004296A (es) Farmaco combinado que comprende gemigliptina y metformina, y metodo para su preparacion.
WO2009104916A3 (fr) Formulations pharmaceutiques destinées au traitement de maladies cardiovasculaires
WO2009125944A3 (fr) Préparation pharmaceutique contenant un inhibiteur des canaux calciques non dihydropyridine et un inhibiteur du récepteur de l'angiotensine 2
WO2010044097A3 (fr) Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci
WO2010044581A3 (fr) Dérivé de biguanide à substitution n1-benzo[1,3]dioxol-5-ylméthyl-n2, procédé de préparation de ce dérivé et composition pharmaceutique le contenant
WO2009125987A3 (fr) Préparation pharmaceutique
WO2010098625A2 (fr) Préparation pharmaceutique
JP2015515971A5 (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09733176

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09733176

Country of ref document: EP

Kind code of ref document: A2